Determination of Copper in Human Urine by RP-LC After Pre-column Derivatization with Neocuproine and Use of Monolithic Column

A selective sensitive RP-LC–UV/VIS method with pre-column derivatization was developed for the determination of copper in human urine at a trace level. This method is based on the selective reaction of 2,9-dimethyl-1,10-phenanthroline (neocuproine) with copper(I) to produce a yellow-orange hydrophobic complex in a neutral or slightly acidic buffer solution (adjusted to pH 5.9). Copper(II) was reduced to copper(I) ions by ascorbic acid as a weak reducer, which was added both to urine sample and mobile phase, respectively. A hydrophobic copper(I)–neocuproine chelate was determined by RP-LC–UV/VIS using a monolithic column Chromolith Performance RP-8e (100 × 4 mm I.D.) at 30.0 ± 0.1 °C with a methanol: aqueous buffer (pH 5.9, ammonium acetate and ascorbic acid 2.8 mmol L^?1) mobile phase at flow rate of 2.00 mL min^?1. Sample injection volume was 20 μL and detection was done at 453 nm. The method was validated over a concentration range of 0.09–11.50 μmol L^?1. The LOD of copper in human urine was found to be 0.07 μmol L^?1 concentration level, suitable for clinical analysis. The precision of the results, reported as the RSD, was below 4.6 % for copper concentration within range 0.5–5.0 μmol L^?1 in the spiked human urine samples.